申请人:ASTELLAS PHARMA INC.
公开号:US20140315963A1
公开(公告)日:2014-10-23
[Problem] A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided.
[Means for Solution] The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.
[问题] 提供了一种作为多巴胺D1受体正变构调节剂(D1 PAM)有用的化合物。
[解决方案] 本发明的发明人已经研究了一种具有多巴胺D1受体正变构调节活性的化合物,该化合物作为用于预防或治疗认知障碍、精神分裂症阴性症状、帕金森病、阿尔茨海默病、亨廷顿病、药物成瘾等的药物组合物的有效成分是有用的,他们因此发现了一种杂环乙酰胺化合物具有多巴胺D1受体正变构调节活性,从而完成了本发明。本发明的杂环乙酰胺化合物具有多巴胺D1受体正变构调节活性,并且可以用作预防或治疗认知障碍、精神分裂症阴性症状、帕金森病、阿尔茨海默病、亨廷顿病、药物成瘾等的药剂。